The Meta-SHIFT Study: How Metabolic Shift Shapes Human Immunometabolism - a Fasting Trial (Meta-SHIFT)

During fasting, the body shifts from using carbohydrates to relying more on fat as its main source of energy. This process is known as the 'metabolic shift'. Fat tissue helps supply this energy by breaking down stored fat into fatty acids, which are released into the bloodstream and transported to organs throughout the body. In addition to fatty acids, many other substances in the blood (such as metabolites) change during fasting to help maintain normal body function.

Immune cells also circulate in the blood and play an important role in protecting the body against infections and diseases such as cancer. However, it is not yet well understood how the metabolic shift during fasting affects immune cell function. The purpose of this study is to investigate how 24 hours of fasting influences immune cell metabolism and function.

Study Overview

• Status: Recruiting
• Conditions: Fasting
• Intervention / Treatment: Other: Fasting

Detailed Description

Rationale: Fasting leads to changes in metabolism and immune function. However, the specific biological connections between these processes are not fully understood. By studying how fasting affects immune cells, this study aims to clarify the bidirectional relationship between metabolism and immune function.

Objectives: The primary objective is to investigate the impact of fasting on immune cells known as peripheral blood mononuclear cells (PBMCs) in healthy adults. The study will examine four main features of these cells:

1. change in basal PBMC energy metabolism;
2. change in activated PBMC energy metabolism;
3. change in the inflammatory capacity of activated PBMCs; and
4. change in PBMC subset abundance.

The secondary objectives are to 1) study how fasting affects PBMC gene expression (whole genome single cell transcriptome) and blood metabolites, 2) identify relationships between changes in metabolites and changes in immune cell function and gene expression, and 3) investigate how fasting-induced changes in gene expression are affected by refeeding. In addition, the explorative objectives are to determine how fasting affects the immune cell population residing in subcutaneous adipose.

Study design: The Meta-SHIFT study is a single-arm intervention study that investigates the effect of fasting by comparing the same subjects 2 hours after meal consumption (fed state or 'baseline') and 24 hours after baseline (fasted state or '24 hours'). Participants will serve as their own control.

Study Population: The study will include twenty-eight healthy adults between 18 and 40 years old, who have a body mass index (BMI) between 18.5-24.9 kg/m2 and no chronic diseases.

Intervention: The evening before the fasting intervention, research participants will consume a standardized dinner (ad libitum). The next morning, two hours before baseline, participants will receive a standardized breakfast shake (energy adjusted for BMR), followed by a fasting period of 26 hours. During the fasting period, research participants are not allowed to eat or drink anything except for water and sugar-free tea provided by the investigators, which may be consumed ad libitum. Two hours after the consumption of the standardized shake, the participants are considered to be in the 'fed state', which is defined as baseline. At baseline, the first blood samples (and optional adipose tissue biopsy) will be taken. At 24 hours after baseline, the participants are considered to be in the 'fasted state', and the second set of blood samples (and optional adipose tissue biopsy) will be taken. A period of 24 hours between sampling points is chosen to prevent the effects of circadian rhythm on the outcome measures. Additionally, the effects of re-introducing food after fasting will be examined (refed state). The refed state is defined as 2 hours after consumption of the second standardized breakfast shake that ends the fasted state, which is 26 hours after baseline. At 26-hours, the third set of blood samples will be collected.

• Study Type: Interventional
• Enrollment (Estimated): 28
• Phase: Not Applicable

Contacts and Locations

• Study Contact: Name: Larissa van der Zon, MS; Phone Number: 607-255-4045; Email: meta-shift@cornell.edu

Study Locations

• United States
  • New York
    • Ithaca, New York, United States, 14853
      • Recruiting
      • Human Metabolic Research Unit, Division of Nutritional Sciences. Cornell University
      • Contact: Sander Kersten, Ph.D.; Phone Number: 607-255-8001; Email: dnsdirector@cornell.edu

Participation Criteria

Eligibility Criteria

• Ages Eligible for Study: Adult
• Accepts Healthy Volunteers: Yes

Description

Inclusion Criteria:

• Apparently healthy
• Age 18-40y at the time of recruitment
• BMI ≥ 18.5 and ≤ 24.9 kg/m2
• Willing to participate in all study activities during the 3-day intervention
• Signed informed consent

Exclusion Criteria:

• Diagnosed with any chronic medical condition that can interfere with the study outcome (e.g., cardiovascular disease, cancer, diabetes mellitus type 1 or 2, liver disease, pulmonary disease, renal disease, inflammatory bowel disease, thyroid disease, long COVID, PASC)
• Bleeding disorder (e.g., Hemophilia A/B, Von Willebrand Disease, or low platelets), current anemia or current use of blood thinners or anticoagulants (e.g. warfarin, heparin)
• Any acute or chronic infection disease or fever in the past month
• Antibiotic use in the past 2 months
• Use of any prescribed medications (incl. GLP-1 agonists), except for contraceptives
• Usage of recreational drugs in the last three months
• Unstable body weight (weight gain or loss >5% of total BW in the past three months)
• Following any restrictive diet within one month of starting the study (for example a ketogenic diet or weight loss diet)
• Fasted for 16 hours or longer in the past week
• History of an eating disorder (e.g., anorexia nervosa, bulimia nervosa, or binge eating disorder)
• Allergic to one or more components of the standardized meal and/or shake (i.e., milk, wheat, and soy)
• Average alcohol intake that exceeds 1 consumption/day or 7 consumptions/week over the past month
• Tobacco smoker or regular use of nicotine products
• Donated or intend to donate blood from 2 months before the study until the end of the study
• Being pregnant or lactating
• Participation in another biomedical study during this study

Study Plan

How is the study designed?

Design Details

• Primary Purpose: Basic Science
• Allocation: N/A
• Interventional Model: Single Group Assignment
• Masking: None (Open Label)

Number of Arms

1

Arms and Interventions

Participant Group / Arm	Intervention / Treatment
Experimental: Fasting; 26-hour fasting	Other: Fasting; After consumption of a standardized breakfast (energy content adjusted to individual BMR), participants will undergo a 26-hour fast (water only), followed by consumption of a second standardized breakfast.

What is the study measuring?

Primary Outcome Measures

Outcome Measure	Measure Description	Time Frame
Change in PBMC energy metabolism.	Change from baseline PBMC glucose dependence (%) and mitochondrial dependence (%) at 24-hours, as measured by the flow cytometry-based CENCAT method.	Baseline, 24 hours
Change in activated PBMC energy metabolism.	Change from baseline activated PBMC glucose dependence (%) and mitochondrial dependence (%) at 24-hours, as measured by the flow cytometry-based CENCAT method. PBMCs are activated in vitro for 2-hours using LPS or TransAct.	Baseline, 24 hours
Change in inflammatory capacity of activated PBMCs.	Change from baseline activated PBMC cytokine positive cells (%) and relative cellular cytokine quantity (fluorescent intensity) at 24-hours, as measured by a flow cytometry-based intracellular cytokine stain. PBMCs are activated in vitro for 2-hours using LPS or TransAct.	Baseline, 24 hours
Change in PBMC subset abundance.	Change from baseline PBMC subset counts, as assessed with a hematology analyzer.	Baseline, 24 hours

Secondary Outcome Measures

Outcome Measure	Measure Description	Time Frame
Change in PBMC transcriptome.	Change from baseline whole genome single cell RNA expression in PBMCs at 24 hours.	Baseline, 24 hours
Change in plasma metabolite profile.	Change from baseline plasma metabolite levels at 24 hours.	Baseline, 24 hours
Change in PBMC RNA expression.	Change from baseline and 24-hour RNA expression of identified fasting target genes in PBMCs at 26 hours.	Baseline, 24 hours, 26 hours

Other Outcome Measures

Outcome Measure	Measure Description	Time Frame
Change in subcutaneous adipose tissue immune cell transcriptome.	Change from baseline whole genome single cell RNA expression in subcutaneous adipose tissue immune cells at 24 hours.	Baseline, 24 hours

Collaborators and Investigators

• Sponsor: Cornell University
• Investigators: Principal Investigator: Sander Kersten, Ph.D., Cornell University

Publications and helpful links

General Publications

• Ruppert PMM, Michielsen CCJR, Hazebroek EJ, Pirayesh A, Olivecrona G, Afman LA, Kersten S. Fasting induces ANGPTL4 and reduces LPL activity in human adipose tissue. Mol Metab. 2020 Oct;40:101033. doi: 10.1016/j.molmet.2020.101033. Epub 2020 Jun 3.

Study record dates

Study Major Dates

• Study Start (Estimated): June 1, 2026
• Primary Completion (Estimated): August 28, 2026
• Study Completion (Estimated): December 1, 2026

Study Registration Dates

• First Submitted: March 26, 2026
• First Submitted That Met QC Criteria: April 6, 2026
• First Posted (Actual): April 14, 2026

Study Record Updates

• Last Update Posted (Actual): May 7, 2026
• Last Update Submitted That Met QC Criteria: May 4, 2026
• Last Verified: April 1, 2026

More Information

Terms related to this study

• Keywords: Fasting; Adipose tissue; Energy metabolism; PBMC
• Additional Relevant MeSH Terms: Behavior; Feeding Behavior; Fasting; Angptl4 protein, mouse
• Other Study ID Numbers: IRB0149920

Drug and device information, study documents

• Studies a U.S. FDA-regulated drug product: No
• Studies a U.S. FDA-regulated device product: No